NCT04868162View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

MRG003

On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or 2.3 mg/kg.

DRUG

MRG003+HX008

On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or the recommended dose by SMC; and HX008 will be administered via intravenous infusion at 3.0 mg/kg

Trial Locations (1)

200123

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Miracogen Inc.

INDUSTRY